Literature DB >> 11529302

Management of malignant pleural effusions.

V B Antony1, R Loddenkemper, P Astoul, C Boutin, P Goldstraw, J Hott, F Rodriguez Panadero, S A Sahn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11529302     DOI： 10.1183/09031936.01.00225601

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  54 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Pleural Neutrophil-to-Lymphocyte Ratio May Be Associated With Early Disease Progression in Stage IV Non-small Cell Lung Cancer.

Authors:  Jeong Uk Lim; Chang Dong Yeo; Hyung Woo Kim; Hye Seon Kang; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Seung Joon Kim; Sang Haak Lee
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose.

Authors:  Najib M Rahman; Eleanor K Mishra; Helen E Davies; Robert J O Davies; Y C Gary Lee
Journal:  Am J Respir Crit Care Med       Date:  2008-06-12       Impact factor: 21.405

4.  Microarray expression profile and analysis of circular RNA regulatory network in malignant pleural effusion.

Authors:  Yakun Wen; Yong Wang; Zhenchuan Xing; Zongjian Liu; Ziliang Hou
Journal:  Cell Cycle       Date:  2018-12-27       Impact factor: 4.534

5.  Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients.

Authors:  K Arapis; R Caliandro; J-B Stern; P Girard; D Debrosse; D Gossot
Journal:  Surg Endosc       Date:  2006-05-02       Impact factor: 4.584

6.  Sodium hydroxide as a sclerosing agent in patients with neoplastic pleural effusion non-candidates for VATS: results of a minimally invasive protocol.

Authors:  Micaela Raices; Matías E Czerwonko; Agustin Dietrich; Alejandro Da Lozzo; Enrique Beveraggi; David Smith
Journal:  Updates Surg       Date:  2017-08-31

7.  Quality Gaps and Comparative Effectiveness of Management Strategies for Recurrent Malignant Pleural Effusions.

Authors:  David E Ost; Jiangong Niu; Hui Zhao; Horiana B Grosu; Sharon H Giordano
Journal:  Chest       Date:  2017-08-31       Impact factor: 9.410

8.  Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.

Authors:  Rosa Filiberti; Stefano Parodi; Roberta Libener; Giovanni Paolo Ivaldi; Pier Aldo Canessa; Donatella Ugolini; Barbara Bobbio; Paola Marroni
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

9.  Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.

Authors:  Ioannis Psallidas; Sophia P Karabela; Charalampos Moschos; Taylor P Sherrill; Androniki Kollintza; Sophia Magkouta; Panagiota Theodoropoulou; Charis Roussos; Timothy S Blackwell; Ioannis Kalomenidis; Georgios T Stathopoulos
Journal:  Mol Cancer       Date:  2010-03-10       Impact factor: 27.401

10.  Does pleural fluid appearance really matter? The relationship between fluid appearance and cytology, cell counts, and chemical laboratory measurements in pleural effusions of patients with cancer.

Authors:  Bulent Ozcakar; Carlos H Martinez; Rodolfo C Morice; Georgie A Eapen; David Ost; Mona G Sarkiss; Hsienchang T Chiu; Carlos A Jimenez
Journal:  J Cardiothorac Surg       Date:  2010-08-18       Impact factor: 1.637
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.